SEREVENT

LOE Approaching

salmeterol xinafoate

NDAINHALATIONPOWDER
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19

Mechanism of Action

LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are…

Clinical Trials (5)

NCT05776927Phase 3Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Started May 2026
304 enrolled
Asthma
NCT03461627Phase 3Unknown

Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma

Started Apr 2017
NCT02113436Phase 4Completed

Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

Started May 2014
300 enrolled
Asthma
NCT01636076Phase 2Completed

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Started Nov 2012
629 enrolled
COPD
NCT01321463Phase 2Completed

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Started May 2011
377 enrolled
Pulmonary Disease, Chronic Obstructive